CAC
JNCE

Cowen and Company’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Cowen and Company’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,647,430
Closed -$4.05M – 757
2022
Q4 		$4.05M Hold
3,647,430
– – 0.42% 37
2022
Q3 		$8.54M Buy
3,647,430
+804,281
+28% +$2.85M 0.82% 29
2022
Q2 		$8.62M Buy
2,843,149
+2,268,814
+395% +$11M 0.83% 29
2022
Q1 		$3.9M Buy
+574,335
New +$4.09M 0.38% 45

Other funds holding JNCE

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Ardent Capital Management Cincinnati, Ohio $241M AUM 23.63% 1-Year Est. Return

Cowen and Company's JNCE Position: Q1 2023 in Review

Cowen and Company sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2023, closing a stake of 3,647,430 shares — an estimated $4.05M sold.

Cowen and Company first reported a position in JNCE in Q1 2022 and held it in 4 quarters. The position peaked at $8.62M in Q2 2022. 84 funds tracked by Wall St. Rank hold JNCE as of Q1 2023.

  • Cowen and Company reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 3,647,430 Jounce Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $4.05M.
  • Cowen and Company first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Cowen and Company's Jounce Therapeutics, Inc. Common Stock position peaked at $8.62M in Q2 2022.
  • 84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.